| Literature DB >> 24658102 |
Zonghuan Li1, Chengyan Xia1, Aixi Yu1, Baiwen Qi1.
Abstract
BACKGROUND: It is controversial whether ultrasound-guided injection of corticosteroid is superior to palpation-guided injection for plantar fasciitis. This meta-analysis was performed to compare the effectiveness of ultrasound-guided and palpation-guided injection of corticosteroid for the treatment of plantar fasciitis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24658102 PMCID: PMC3962443 DOI: 10.1371/journal.pone.0092671
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow diagram of the process of literature screening.
General characteristics of included studies.
| Included study | Location | Sample size | Mean age (years) | Mean BMI | Intervention | Comparison | Study design | Outcomes | Follow-up duration |
| Ball 2013 | United Kingdom | 44 | 49 | 30.7/31.8 | ultrasound-guided injection of 0.5 ml (20 mg) methylprednisolone acetate and 0.5 ml saline | palpation-guided injection of 0.5 ml (20 mg) methylprednisolone acetate and 0.5 ml saline | RCT | VAS, HTI PFT, RR | 12 weeks |
| Chen 2013 | China | 32 | 55 | 27.09/28.27 | device-assisted ultrasound-guided injection of 7 mg (1 ml) betamethasone and 5 mg (0.5 ml) lidocaine | palpation-guided injection of 7 mg (1 ml) betamethasone and 5 mg (0.5 ml) lidocaine | RCT | VAS, TT, PFT, HPT, Hypoechogenicity | 3 months |
| Kane 2001 | Ireland | 23 | 58 | 30.4 | ultrasound-guided injection of triamcinolone hexacetonide and xylocaine into the plantar fascia | palpation-guided injection of triamcinolone hexacetonide and xylocaine into the plantar fascia | RCT | VAS, HTI, PFT, RR | 13.4 weeks |
| Tsai 2006 | China | 25 | 51 | 25.1/26.9 | sonographically-guided injection of 7 mg (1 ml) dexamethasone and 5 mg (0.5 ml) lidocaine | palpation-guided injection of 7 mg (1 ml) dexamethasone and 5 mg (0.5 ml) lidocaine | RCT | VAS, TT, PFT, RR, hypoechogenicity | 1 year |
| Yucel 2009 | Turkey | 21 | 46 | 28.7/28.5 | ultrasound-guided injection of 0.5 ml betamethasone dipropionate (6.43 mg/ml) and betamethasone sodium phosphate (2.63 mg/ml) combination, and 0.5ml prilocaine-HCl(20mg/ml) | palpation-guided injection of 0.5 ml betamethasone dipropionate (6.43 mg/ml) and betamethasone sodium phosphate (2.63 mg/ml) combination, and 0.5ml prilocaine-HCl(20mg/ml) | RCT | VAS, PFT, HPT, hypoechogenicity | 25.3 months |
−/−: ultrasound-guided injection/palpation-guided injection. BMI: body mass index; RCT: randomization controlled trial; VAS: visual analogue score; TT: tenderness threshold; HTI: heel tenderness index; PFT: plantar fascia thickness; HPT: heel pad thickness; RR: response rate.
Risk of bias of included studies.
| Included study | Random sequence generation | Allocation concealment | Blinding of patients | Blinding of therapists | Incomplete outcome data | Selective reporting | Other bias |
| Ball 2013 | Low | Unclear | Low | Unclear | Low | Low | Unclear |
| Chen 2013 | Unclear | Unclear | Unclear | High | Low | Low | Unclear |
| Kane 2001 | Unclear | Unclear | Unclear | Unclear | Low | Low | Unclear |
| Tsai 2006 | Unclear | Unclear | Unclear | Unclear | Low | Low | Unclear |
| Yucel 2009 | Unclear | Unclear | Unclear | Unclear | Low | Low | Unclear |
Figure 2Forest plot for VAS score between ultrasound-guided injection and palpation-guided injection.
Figure 3Forest plot for tenderness threshold between ultrasound-guided injection and palpation-guided injection.
Figure 4Forest plot for heel tenderness index between ultrasound-guided injection and palpation-guided injection.
Figure 5Forest plot for response rate between ultrasound-guided injection and palpation-guided injection.
Figure 6Forest plot for plantar fascia thickness between ultrasound-guided injection and palpation-guided injection.
Figure 7Forest plot for hypoechogenicity between ultrasound-guided injection and palpation-guided injection.
Figure 8Forest plot for heel pad thickness between ultrasound-guided injection and palpation-guided injection.
GRADE assessment of outcomes.
| Outcome | Quality assessment | Quality | Importance | ||||||
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | |||
| VAS | 5 | RCT | seriousa | no serious inconsistency | no serious indirectness | no serious imprecision | Undetected | Moderate | Critical |
| TT | 2 | RCT | seriousa | no serious inconsistency | no serious indirectness | no serious imprecision | Undetected | Moderate | Critical |
| Response rate | 3 | RCT | seriousa | seriousb | no serious indirectness | no serious imprecision | Undetected | Low | Critical |
| HTI | 2 | RCT | seriousa | seriousb | no serious indirectness | no serious imprecision | Undetected | Low | Important |
| PFT | 4 | RCT | seriousa | no serious inconsistency | no serious indirectness | no serious imprecision | Undetected | Moderate | Important |
| HPT | 2 | RCT | seriousa | seriousb | no serious indirectness | no serious imprecision | Undetected | Low | Important |
| Hypoechogenicity | 3 | RCT | seriousa | no serious inconsistency | no serious indirectness | no serious imprecision | Undetected | Moderate | Important |
a Random sequence generation, allocation concealment and blind method were not reported in most studies.
b The heterogeneity among included studies was not neglectable.
RCT: randomization controlled trial; VAS: visual analogue score; TT: tenderness threshold; HTI: heel tenderness index; PFT: plantar fascia thickness; HPT: heel pad thickness.